MedTrace Logo

Nilotinib and Imatinib Mesylate in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia

NCT00769327 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 129

Last updated 2022-01-04

No results posted yet for this study

Summary

RATIONALE: Nilotinib and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

PURPOSE: This phase II trial is studying how well giving nilotinib together with imatinib mesylate works in treating patients with early chronic phase chronic myelogenous leukemia.

Conditions

Interventions

DRUG

imatinib mesylate

DRUG

nilotinib

GENETIC

cytogenetic analysis

GENETIC

fluorescence in situ hybridization

GENETIC

microarray analysis

GENETIC

mutation analysis

GENETIC

polymerase chain reaction

GENETIC

polymorphism analysis

OTHER

laboratory biomarker analysis

Sponsors & Collaborators

  • Gruppo Italiano Malattie EMatologiche dell'Adulto

    lead OTHER

Principal Investigators

  • Michele Baccarani, MD · Gruppo Italiano Malattie EMatologiche dell'Adulto

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-09
Primary Completion
2014-10-31
Completion
2014-10-10

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00769327 on ClinicalTrials.gov